Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 with SCRT or LCCRT in Rectal Adenocarcinoma
NCT05254327Phase 2Recruiting
- Sponsor
- University of Nebraska
- Start
- Aug 2022
- Primary completion
- May 2030
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of manganese butoxyethyl pyridyl porphyrin in rectal adenocarcinoma (4 arms), sponsored by University of Nebraska. Primary endpoints: Grade 3 and above associated with gastrointestinal Toxicities at 3 weeks, Grade 3 and above associated with genitourinary Toxicities at 3 weeks and 2 more. Started Aug 2022; status: recruiting.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05254327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254327.